Protagonist Therapeutics, Inc.
A biotechnology company that designs oral and injectable peptide drugs for chronic conditions like psoriasis, blood disorders, and obesity. Founded in 2006 on peptide technology from the University of Pennsylvania, it was incubated in Australia before moving to California. Its name was chosen to suggest a central role in peptide medicine, and its psoriasis pill Icotyde is licensed to Johnson & Johnson.
Granted 129.7K · Sold 129.7K
Granted 15.0K · Sold 15.0K
Granted 24.0K · Sold 24.0K
Granted 36.0K · Sold 59.1K
Granted 24.8K · Sold 26.5K
Granted 27.0K · Sold 27.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Patel Dinesh V PH DPresident and CEO, Director · 8 transactions | +3.4% | 598.5K | 129.7K | — | 129.7K |
| Molina Arturo MDChief Medical Officer · 2 transactions | +11.2% | 99.1K | 15.0K | — | 15.0K |
| Selick Harold EDirector · 2 transactions | +39.4% | 84.8K | 24.0K | — | 24.0K |
| Giraudo BryanDirector · 6 transactions | — | 64.5K | 36.0K | — | 59.1K |
| Ali AsifChief Financial Officer · 4 transactions | -2.2% | 59.0K | 24.8K | — | 26.5K |
| Waddill William D.Director · 7 transactions | 0% | 7.8K | 27.0K | — | 27.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -281.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.